Tenofovir/emtricitabine
| Combination of | |
|---|---|
| Tenofovir | Nucleotide analogue reverse transcriptase inhibitor |
| Emtricitabine | Nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Pregnancy cat. | B (US) |
| Legal status | POM (UK) ℞-only (US) |
| Routes | Oral |
| Identifiers | |
| ATC code | J05AR03 |
| PubChem | CID 11954236 |
| NIAID ChemDB | 214126 |
 (what is this?) (verify) |
|
Tenofovir/emtricitabine, trademark Truvada, is a fixed-dose combination of two antiretroviral drugs used for the treatment of HIV. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine. By combining the two agents into one tablet, it reduces the pill burden and increases compliance with antiretroviral therapy. The drug has also found some potential as a preventative measure if taken daily or weekly leading up to exposure, though human clinical trials are ongoing.[1]
[edit] Clinical studies
The HEAT study (randomized, double-blind, placebo-matched, multicentre) showed that once-daily emtricitabine/tenofovir plus lopinavir/ritonavir or boosted atazanavir or efavirenz were effective in the initial treatment of patients with HIV-1 infection (with screening plasma HIV-1 RNA levels of ≥1,000,000 copies/mL in ACTG 5202).[2]
In other randomized studies, emtricitabine/tenofovir DF 200 mg/300 mg once daily was an effective backbone for boosted PI-based regimens in the initial treatment of HIV-1 infection.[2][3]
Emtricitabine/tenofovir DF in combination with various boosted PIs was generally well tolerated by adults with HIV-1 infection.[2]
Truvada was developed by Gilead Sciences and approved by the United States Food and Drug Administration in 2004.
A combination pill containing Truvada and efavirenz (Sustiva) is also available and is marketed as Atripla.
[edit] References
- ^ Gilead Pill Slashes HIV Risk in 'Breakthrough' Study, SFGate.com [Launched: November 26, 2010].
- ^ a b c Perry CM.[1].Drugs 2009;69(7):843-857.doi: 10.2165/00003495-200969070-00005.
- ^ Jon Cohen (3 December 2010). "A Powerful and Perplexing New HIV Prevention Tool". Science 330: 1298. doi:10.1126/science.330.6009.1298.
[edit] External links
- Truvada website, run by Gilead Sciences
- Global iPrEx study website
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
